Brief: Vor Biopharma Says Primary Endpoint Achieved In Phase 3 Clinical Study Evaluating Telitacicept
08/11/2025 16:47
Nov 8 (Reuters) - Vor Biopharma Inc VOR.O: PRIMARY ENDPOINT ACHIEVED IN STAGE A OF A PHASE 3 CLINICAL STUDY EVALUATING TELITACICEPT IN ADULTS WITH IGA NEPHROPATHY Source text: ID:nGNX6wP7Tm Further company coverage: VOR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vor Biopharma
See all newsBrief: Telitacicept Demonstrates Durable Preservation Of Kidney Function Through Two Years In Phase 3 Teligan Trial In Iga Nephropathy
Vor Bio says its experimental drug slowed loss of kidney function in late-stage study
U.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning